| Autor: |
Allan, J.E.M., Buist, H.E., Chapman, A., Flament, G., Hartmann, C., Jawad, I., Kuijpers, L.T., Kuittinen, H., Meier, I., Noyons, E., Giessen, A.M. van der, Yegros, A. |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Popis: |
New ways to diagnose and treat diseases are being sought to address the increasingly global societal challenge of achieving healthy and long life for as many as possible. In Europe, goals have been set to raise by two years the length of the average healthy lifespan of Europeans by 2020. Cardiovascular disease, cancer and diabetes were responsible for more than 70% of deaths from non-communicable diseases globally in 2012. Infectious diseases are also one of the leading worldwide causes of death in adults and were responsible for 16% of all deaths in 2012. Neurodegenerative diseases are increasingly affecting the ageing populations of the more developed countries, currently costing approximately EUR 130 billion per annum for care for people with dementia in Europe. The socio-economic cost of dealing with these and other diseases is mounting as the population grows and ages – in diagnosis and treatment, in the quality of life of the sufferers, and those who care for them, and in losses to the economy. The five health sub-sectors selected for review in this project are those mentioned above – cancer, cardiovascular disease, diabetes, infectious diseases and neurodegenerative diseases1. This report offers a snapshot of the status of the environment for nanotechnology in the context of health. Analysis of that environment, trends in the data and the effects of European policies and actions on health nanotechnology will be reported in the NanoData Health Impact Assessment and are therefore not included in this report. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
